Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Long Term Debt

As of the most recent data (June 2026), BLACR shows a long-term debt of $280K. That compares with $20K in the prior-year period — up 1248.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLACR's long-term debt is now $280K (was $20K) — a 1248.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is outperforming or lagging.

Tracking BLACR's long-term debt over time shows whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is scaling, shrinking, or reshaping that part of the business. The current reading is $280K That compares with $20K in the prior-year period — up 1248.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $280K) with ownership activity and broader fundamentals.